Bioavailability of oral cyclosporine in healthy Mexican volunteers: Evidence for interethnic variability

Journal of Clinical Pharmacology

Volumn 37, Issue 7, 1997, Pages 630-634

  Palma Aguirre, J Antonio ^a   González Llaven, José ^b   Flores Murrieta, Francisco J ^c   Castañeda Hernández, Gilberto ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; NIFEDIPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG HALF LIFE; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEXICO; NORMAL HUMAN; ORAL DRUG ADMINISTRATION;

EID: 1842364892     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04346.x     Document Type: Article

References (24)

1. Kalow W: Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991;12:102-107.
2. Daly AK, Cholerton S, Gregory W, Idle JR: Metabolic polymorphisms. Pharmacol Ther 1993;57:129-160.
3. Vesell ES: Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther 1977;22:659-679.
4. Darmansjah I, Muchtar A: Dose response variation among different populations. Clin Pharmacol Ther 1992;52:449-452.
5. Kahan BD: Cyclosporin. N Engl J Med 1989;321:1725-1738.
6. Keown PA, Stiller CR, Laupacis AL, Howson W, Coles R, Stawechi M, et al: The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 1982;14:659-661.
7. Reymond JF, Steimer JL, Niederberger W: On the dose dependency of cyclosporine A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 1988;16:331-353.
8. Wu CY, Benet LZ, Herbert MF, Gupta SK, Rowland M, Gómez DY, Wacher VJ: Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-497.
9. Lindholm A: Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991;13:465-477.
10. Gupta SK, Manfro RC, Tomlanovich SJ, Gambertoglio JG, Gavoroy MR, Benet LZ: Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990;30:643-653.
11. Lindholm A, Henricsson S, Dahlqvist R: The effect of food and bile acid administration on the relative bioavailability of cyclosporine. Br J Clin Pharmacol 1990;29:541-548.
12. Lindholm A, Welsh M, Alton C, Kahan BD: Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992;52:359-371.
13. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI: Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet 1995;29(suppl 1):33-44.
14. Castañeda-Hernández G, Hoyo-Vadillo C, Palma-Aguirre JA, Flores-Murrieta FJ: Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993;33:140-145.
15. Hoyo-Vadillo C, Castañeda-Hernández G, Herrera JE, Vidal-Gárate J, Moreno-Ramos A, Chávez F, Hong E: Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. J Clin Pharmacol 1989;29: 816-820.
16. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG, George CF: Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991;31:399-403.
17. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF, Amanullah M: The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54:329-338.
18. Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG: Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmncol 1995; 40:489-493.
19. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF: Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995;40:51-58.
20. Castañeda-Hernández G, Palma-Aguirre JA, Montoya-Cabrera MA, Flores-Murrieta FJ: Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol 1996;41:433-434.
21. Mueller EA, Kovarik JM, Koelle EU, Merdjan H, Johnston A, Hitzenberger G: Pharmacokinetics of cyclosporine and multiple-dose diclofenac during coadministration. J Clin Pharmacol 1993; 33:936-943.
22. Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grape-fruit juice. Clin Pharmacol Ther 1995;57:485-491.
23. 1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 1990;11:2275-2279.
24. Bailey DG, Arnold JMO, Spence D: Grapefruit juice and drugs: how significant the interaction? Clin Pharmacokinet 1994; 26:91-98.